LUCID DIAGNOSTICS INC. LUCD 深 沪
已收盘 09-20 16:00:00 美东时间
0.8249
+0.006
+0.76%
华盛通- 最 高0.8336
- 今 开0.83
- 成交量 17.89万股
- 最 低 0.81
- 昨 收 0.8187
- 总市值 3959.45万
- 52周最高 1.58
- 市盈率 静 --
- 换手率 0.37%
- 52周最低 0.6301
- 委 比 33.33%
- 总股本 4799.91万
- 历史最高 13.52
- 量 比 0.75
- 振 幅 2.88%
- 历史最低 0.6301
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lucid Diagnostics to be deconsolidated from PAVmed's financial statements
PAVmed (NASDAQ:PAVM) on Monday said that as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) will be de-consolidated from PAVmed's financial...
09-17 15:33
Lucid Diagnostics Launches New Corporate Website
NEW YORK, July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (...
07-11 20:31
Lucid Diagnostic Reports 4,000 Firefighter Undergoes EsoGuard Esophageal Precancer Testing
Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF
06-12 20:11
Lucid Diagnostics Insights: Performance and Outlook Update
Lucid Diagnostics (LUCD) has shared an announcement. The recent disclosure prov...
05-14 18:23
Lucid Diagnostics(LUCD.US)：2024年Q1财报实现营收100.1万美元，前值为44.6万美元，预期值为105万美元；每股收益为-0.21美元，前值为-0.24美元，预期值为-0.27美元。
Lucid Diagnostics(LUCD.US)：2024年Q1财报实现营收100.1万美元，前值为44.6万美元，预期值为105万美元；每股收益为-0....
05-13 20:04
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck® unaffected by recall and remains the gold standard for non-endoscopic cell collect...
05-09 19:49
Lucid Diagnostics Highlights Promising EsoGuard Study Results
Lucid Diagnostics (LUCD) has provided an announcement. Lucid Diagnostics Inc. h...
05-03 05:12
Needham：重申Lucid Diagnostics(LUCD.US)评级，由买入调整至买入评级, 目标价2.50美元。
Needham：重申Lucid Diagnostics(LUCD.US)评级，由买入调整至买入评级, 目标价2.50美元。
04-12 16:40
Lucid Diagnostics reports preliminary Q4 results
Lucid Diagnostics (NASDAQ:LUCD) said Monday its fourth quarter EsoGuard revenue was $1.04 million. The company said its CLIA-certified clinical laboratory performed 2,201 commercial EsoGuard Esophagea...
03-26 05:55
Earnings Scheduled For March 25, 2024
Companies Reporting Before The Bell • Bitcoin Depot (NASDAQ:BTM) is expected to report quarterly loss at $0.08 per share on revenue of $161.50 million.
03-25 17:33
